PDL BioPharma Inc. (PDLI)

2.56
NASDAQ : Health Technology
Prev Close 2.55
Day Low/High 2.47 / 2.57
52 Wk Low/High 2.25 / 3.89
Avg Volume 1.04M
Exchange NASDAQ
Shares Outstanding 114.20M
Market Cap 291.22M
EPS -0.50
P/E Ratio 8.79
Div & Yield N.A. (N.A)
Health Stocks in Motion

Health Stocks in Motion

Impax Labs falls 23%.

Early Stocks in Motion

Protein Design beats estimates.

Protein Design Lifts Forecast

The company reported quarterly earnings that were ahead of Wall Street's estimates.

Cheers for Protein Design

The stock pops on news of a pact with Biogen Idec.

Biogen Pact Boosts Protein Design

The companies will work to develop and commercialize three phase II antibody products.

Biotech Under the Microscope

In a climate of low volatility, Dan Fitzpatrick examines charts of Genentech and others.

Biotech Under the Microscope

In a climate of low volatility, Dan Fitzpatrick examines charts of Genentech and others.

Digest Protein Design's Gains

Longs have no cause to sell as the company absorbs its breakout gains. Plus the Nasdaq and more.

History Suggests QQQQ's Run Isn't Over

Its recent climb makes it seem like a good short, but history says otherwise. Plus, TiVo and more.

Health Stocks in Motion

Health Stocks in Motion

Regeneration Tech falls on weak quarter.

Nearing a New Support Level?

The Arms Index's 10-day moving average is quite oversold, kindling prospects of an imminent rally.

Health Stocks in Motion

Health Stocks in Motion

Neurochem tumbles on late-stage trial failure.

Gradual Reanimation in Biotech Sector

Signs of life are returning to these stocks. Here are three that could outperform the rest.

Protein Design Off on Drug Move

Protein Design Off on Drug Move

The company will not seek fast-track regulatory approval for its colitis treatment.

Early Tech Stocks in Motion

Early Tech Stocks in Motion

TiVo shares rise 49% on a contract with Comcast.

Health Stocks in Motion

Health Stocks in Motion

Kyphon tumbles on weak 2005 guidance.

Biotech to Lose Legs

The technical prognosis says the sector's running days are over for a while.

Ready to Turn Lower in the Short Run

Indicators signal that an intermediate-term high is near.

Health Stocks in Motion

Health Stocks in Motion

Cyberonics falls after rebuffing takeover offer.

The Long View Still Looks Good

We may be a little overdone to the upside in the short term, but the long-term picture is encouraging.

Test Data Hurt Protein Design

The biotech company drops plans to pursue antibody as treatment for colitis.

Market Slowly Accepts the Truth About Rates

Earnings news returns to the fore as rate fears get factored in.

Use the News to Avoid the Trading Churn

Keep abreast of events that will bring volatility and trading opportunities back to the market.

No Joy for Protein Design, Genentech Trial

You can't rule out the possibility that a deal is inked, but for which drugs and on what terms?

Pressure's Building Toward Year-End

Which way will it break? In a special section, Alan gives his trading outlook for December.

Protein Design Labs Loss Widens on Charges

Excluding one-time items, the company's loss topped estimates.

A Genentech-Protein Design Punchout Over Avastin?

Some signals indicate Genentech may want to pull out of the licensing deal.

Rough Day for the Biotech Sector

Rough Day for the Biotech Sector

The selling was widespread on a day the overall market also slumped.

Genentech Science, Shares Get Major Boost

Genentech Science, Shares Get Major Boost

Its Avastin proves effective vs. colon cancer in a Phase III trial.

Shifting Gears

Trading will be tricky heading into options expiration, so shorten your holding period and tighten your stops.

TheStreet Quant Rating: C- (Hold)